Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:52:29.247Z.
Calculation as of: 2026-10-06T18:52:29.247Z.
Quote observation: 2026-10-06T18:50:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869efbf6e11e98c8b36b953a9b631e7639c239a9e2012f11ad9cca4b0e6b7a7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$629.87M
EV/EBITDA Ratio
12.00x
TTM Avg
14.05x
3Y Avg
14.05x
5Y Avg
17.93x
Market Cap
$662.48M
EV/EBITDA Ratio
25.88x
TTM Avg
12.95x
3Y Avg
19.43x
5Y Avg
199.83x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $635.70M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $636.13M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $644.80M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $629.87M | 12.00x | 14.05x | 14.05x | 17.93x |
| SOPHiA GENETICS S.A. (SOPH)vs › | $625.86M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $618.02M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $656.86M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $662.48M | 25.88x | 12.95x | 19.43x | 199.83x |
| ArriVent BioPharma, Inc. (AVBP)vs › | $668.36M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $669.43M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
